Physicians' Academy for Cardiovascular Education

A call to action: optimizing treatment in CKD

4 things to know about CKD and SGLT2i - lecture 3 out of 4

Listen to the podcast
10' education - Mar. 22, 2023 - Prof. Meg Jardine, MD, PhD - Sydney, Australia

Video navigation menu

  • KDIGO DKD guidelines 0:30
  • Prescription of SGLT2i in practice 1:34
  • Adherence 5:32
  • Barriers to uptake 6:52
  • KDIGO tools for SGLT2i initiation  8:12

In which patient population is prescription of SGLT2 inhibitors the lowest?

  • A. In patients with T2DM without CKD
  • B. In patients with T2DM and CKD
  • C. Presciption is similar in patients with T2DM with and without CKD
Show the correct answer


Show transcript

Educational information

This educational video is part of a series called '4 Things to know about CKD and SGLT2i'.


Professor Meg Jardine is the Director of the CTC and the CTC’s Kidney Health Research Director at the University of Sydney, Australia.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant received from AstraZeneca.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: